Replies to post #37689 on OncoSec Medical Inc (ONCSQ)

[Titan V]

Another successful spin-out from KU Leuven:

KU Leuven spin-out in Alzheimer’s alliance with Roche worth a potential €500M
http://sciencebusiness.net/news/67844/KU-Leuven-spin-out-in-Alzheimer%E2%80%99s-alliance-with-Roche-worth-a-potential--and-euro%3B500M

Leuven seems to be an innovative university:

KU LEUVEN SPIN-OFF THROMBOGENICS ENTERS INTO COMMERCIALIZATION AGREEMENT FOR OCRIPLASMIN (w/ Novartis)
https://lrd.kuleuven.be/en/news/ku-leuven-spin-off-thrombogenics-enters-into-commercialisation-agreement

Pfizer Inks Deal with K.U. Leuven for HIV Drugs with New Mechanism of Action
http://www.genengnews.com/gen-news-highlights/pfizer-inks-deal-with-k-u-leuven-for-hiv-drugs-with-new-mechanism-of-action/81243931

VIB (KU Leuven) and CD3 join forces with AstraZeneca for the development of MALT1 inhibitors
http://www.cd3.eu/success-stories/vib-and-cd3-join-forces-with-astrazeneca-for-the-development-of-malt1-inhibitors

If ONCS + KU Leuven tech is really very promising, I do not see them having difficulty in securing a partner, looking at Leuven's track record.